In this large observational study, similar and, in some instances, more favorable neonatal and maternal outcomes were observed in pregnancies exposed to buprenorphine combined with naloxone compared to pregnancies exposed to buprenorphine alone.
In this large cohort study analyzing data from publicly insured Medicaid beneficiaries, the overall risk of malformations was lower with buprenorphine than with methadone.
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Parenting support, maternal bonding with the infant, engagement in an OUD treatment program, and recovery-specific support systems promoted recovery in postpartum women with opioid use disorders.
This study demonstrates higher rates of treatment continuation in postpartum women with opioid use disorders if medication treatment (methadone or buprenorphine) is initiated early and maintained throughout pregnancy.
The use of opioid drugs in women of childbearing age has become a pressing public health concern. Â It is clear that opiate use during pregnancy puts the mother and child at risk; opiate use during [...]
We have been writing over the last few years about the growing problem of opioid use and abuse in women of reproductive age. Â Responding to a dramatic increase in the number of women abusing opiates [...]
Over the last week, there have been quite a few articles in the press detailing the increase in opioid use in the United States, focusing the impact of this epidemic on infants and children. According [...]
The use of opioid drugs in women of childbearing age has become a pressing public health concern. Â It is clear that opiate use during pregnancy puts the mother and child at risk; opiate use during [...]
